ClinicalTrials.gg
CompletedNCT01512108Updated Dec 18, 2017Results posted

Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

A Phase 3 interventional study of liraglutide and oral anti-diabetic drug in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 36 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-12-18.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
32nd of 151
363 · median 62
Started
2012
with 20 others
Phase 3
45 of 151
1 open now
Registered
45th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 32nd largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 45th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial was conducted in Japan. The aim of this trial was to evaluate the safety and efficacy of once daily administration of liraglutide in combination with an oral anti-diabetic drug (OAD) in Japanese subjects with type 2 diabetes who are insufficiently controlled on OAD monotherapy. All subjects will continue their pre-trial OAD (either glinide, metformin, alpha-glucosidase inhibitor or thiazolidinedione) during the trial at unchanged type and dose.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 363 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject.)
  • Japanese subjects with type 2 diabetes on monotherapy with an OAD (either glinide, metformin, a-glucosidase inhibitor or thiazolidinedione) within approved Japanese labelling in addition to diet and exercise therapy. Total daily dose and type of drug should have remained unchanged for at least 8 weeks prior to Visit 1
  • Type 2 diabetes mellitus (clinically diagnosed) for at least 6 months
  • between 7.0-10.0% (both inclusive)
  • (BMI) below 40.0 kg/m\^2
  • Outpatients who have no plans for an educational hospitalisation for the purpose of glycaemic control. However, hospitalisation for training of self-injection from Visit 2 that is for no longer than one week is allowed
  • Subjects able and willing to perform self-monitoring of plasma glucose (SMPG)

Exclusion criteria

Exclusion Criteria:

  • Subjects with known or previous malignant tumor and are strongly suspected of recurrence (except basal cell skin cancer or squamous cell skin cancer)
  • Calcitonin above or equal to 160 pg/mL
  • Personal history of non-familial medullary thyroid carcinoma
  • Family or personal history of multiple endocrine neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma (FMTC)
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months
  • Treatment with GLP-1 receptor agonist or dipeptidyl peptidase 4 (DPP-4) inhibitor within 12 weeks prior to Visit 1
  • Having to liraglutide and any of the OADs (according to Japanese labelling)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Liraglutide + an OAD therapy

    Drug: liraglutide

  • Active comparator
    Two OADs combination therapy

    Drug: oral anti-diabetic drug

Interventions

  • 0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).

  • Drugoral anti-diabetic drug

    An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.

07

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (AEs)

    Adverse events were defined as events occurring after administration of trial product and no later than 7 days after last day of treatment. Severe AEs: considerable interference with subject's daily activities. Moderate AEs: Marked symptoms, moderate interference with the subject's daily activities. Mild AEs: No or transient symptoms, no interference with the subject's daily activities. Serious AEs: AEs that resulted in any of the following: death, a life-threatening experience, hospitalization/prolongation of existing hospitalization, persistent/significant disability, and congenital anomaly.

    Time frame: Week 0 to Week 52 + 7 days

Secondary outcomes

  1. Number of Confirmed Hypoglycaemic Episodes

    Confirmed hypoglycaemic episodes consisted of the pool of episodes of severe hypoglycaemia as well as minor hypoglycaemic episodes \[An episode with symptoms consistent with hypoglycaemia with confirmation by plasma glucose \<3.1 mmol/L (56 mg/dL) or full blood glucose \<2.8 mmol/L (50 mg/dL) and which is handled by the subject himself or herself or any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or full blood glucose value \<2.8 mmol/L (50 mg/dL)\] with a confirmed plasma glucose value of less than 3.1 mmol/L (56 mg/dL).

    Time frame: Week 0 to Week 52

  2. Change in HbA1c From Baseline to Week 52

    Estimated mean change in HbA1c from baseline after 52 Weeks of treatment

    Time frame: Week 0, week 52

  3. Change in FPG From Baseline to Week 52

    Estimated mean change from baseline in FPG after 52 Weeks of treatment

    Time frame: Week 0, week 52

08

Results

Posted May 28, 2014

Participant flow

The trial was conducted at 36 sites in Japan.

Participant flow — Overall Study
MilestoneLiraglutide 0.9 mg/DayAdditional OAD
Started243120
Exposed240120
Completed221111
Not completed229
Withdrew: Adverse event94
Withdrew: Protocol violation12
Withdrew: Withdrawal criteria10
Withdrew: Unclassified113

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Events (AEs)

Adverse events were defined as events occurring after administration of trial product and no later than 7 days after last day of treatment. Severe AEs: considerable interference with subject's daily activities. Moderate AEs: Marked symptoms, moderate interference with the subject's daily activities. Mild AEs: No or transient symptoms, no interference with the subject's daily activities. Serious AEs: AEs that resulted in any of the following: death, a life-threatening experience, hospitalization/prolongation of existing hospitalization, persistent/significant disability, and congenital anomaly.

Time frame:
Week 0 to Week 52 + 7 days
Reported as:
Number · Events/100 years of patient exposure
Incidence of Treatment Emergent Adverse Events (AEs)
Events/100 years of patient exposureLiraglutide 0.9 mg/DayAdditional OAD
All AEs361331
Mild AEs345321
Moderate AEs149
Severe AEs22
Serious AEs59
SecondaryNumber of Confirmed Hypoglycaemic Episodes

Confirmed hypoglycaemic episodes consisted of the pool of episodes of severe hypoglycaemia as well as minor hypoglycaemic episodes \[An episode with symptoms consistent with hypoglycaemia with confirmation by plasma glucose \<3.1 mmol/L (56 mg/dL) or full blood glucose \<2.8 mmol/L (50 mg/dL) and which is handled by the subject himself or herself or any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or full blood glucose value \<2.8 mmol/L (50 mg/dL)\] with a confirmed plasma glucose value of less than 3.1 mmol/L (56 mg/dL).

Time frame:
Week 0 to Week 52
Reported as:
Number · episodes
Number of Confirmed Hypoglycaemic Episodes
episodesLiraglutide 0.9 mg/DayAdditional OAD
Number of Confirmed Hypoglycaemic Episodes72
SecondaryChange in HbA1c From Baseline to Week 52

Estimated mean change in HbA1c from baseline after 52 Weeks of treatment

Time frame:
Week 0, week 52
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in HbA1c From Baseline to Week 52
percentage of glycosylated haemoglobinLiraglutide 0.9 mg/DayAdditional OAD
Change in HbA1c From Baseline to Week 52-1.21 ± 0.05-0.94 ± 0.07
Statistical analysis
  • Liraglutide 0.9 mg/Day vs Additional OAD · ANOVA · p = 0.0026 · Estimated treatment difference, mean: -0.27 · 95% CI -0.44 to -0.09
SecondaryChange in FPG From Baseline to Week 52

Estimated mean change from baseline in FPG after 52 Weeks of treatment

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in FPG From Baseline to Week 52
mmol/LLiraglutide 0.9 mg/DayAdditional OAD
Change in FPG From Baseline to Week 52-1.55 ± 0.09-1.24 ± 0.12
Statistical analysis
  • Liraglutide 0.9 mg/Day vs Additional OAD · ANOVA · p = 0.0458 · Estimated treatment difference, mean: -0.30 · 95% CI -0.60 to -0.01

Adverse events

Collected over Adverse events were captured from the time of consent until 52 weeks of treatment and if needed were followed up after the final visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 0.9 mg/Day—11/240 (4.6%)161/240 (67.1%)
Additional OAD—10/120 (8.3%)77/120 (64.2%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventLiraglutide 0.9 mg/DayAdditional OAD
Deafness neurosensoryEar and labyrinth disorders0/2401/120
Chest painGeneral disorders0/2401/120
Meningitis herpesInfections and infestations0/2401/120
Foot fractureInjury, poisoning and procedural complications0/2401/120
Road traffic accidentInjury, poisoning and procedural complications0/2401/120
OsteoarthritisMusculoskeletal and connective tissue disorders0/2401/120
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2401/120
Gastric cancer stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2401/120
Large intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2401/120
Limb operationSurgical and medical procedures0/2401/120
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLiraglutide 0.9 mg/DayAdditional OAD
NasopharyngitisInfections and infestations89/24047/120
ConstipationGastrointestinal disorders44/24012/120
Diabetic retinopathyEye disorders21/24016/120
NauseaGastrointestinal disorders31/2404/120
DiarrhoeaGastrointestinal disorders20/2409/120
Abdominal discomfortGastrointestinal disorders19/2401/120
CataractEye disorders8/2408/120
Back painMusculoskeletal and connective tissue disorders13/2403/120
Dental cariesGastrointestinal disorders7/2406/120
InfluenzaInfections and infestations8/2406/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)Liraglutide 0.9 mg/DayAdditional OADTotal
Mean59.6 ± 11.659.2 ± 10.259.5 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 0.9 mg/DayAdditional OADTotal
Female584098
Male18280262
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)Liraglutide 0.9 mg/DayAdditional OADTotal
Mean8.1 ± 0.88.1 ± 0.88.1 ± 0.8
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)Liraglutide 0.9 mg/DayAdditional OADTotal
Mean8.68 ± 1.618.96 ± 1.828.77 ± 1.69
09

Study locations

36 sites
  • Novo Nordisk Investigational Site
    Chuo-ku, Tokyo, 103 0002, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku, Tokyo, 103 0027, Japan
  • Novo Nordisk Investigational Site
    Ehime, Japan, 790 0067, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, Japan, 810 8798, Japan
  • Novo Nordisk Investigational Site
    Fukuoka-shi, Fukuoka, 815 8555, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, 812 0025, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, 818 8502, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, 820 8505, Japan
  • Novo Nordisk Investigational Site
    Kamagaya-shi, Chiba, 273 0121, Japan
  • Novo Nordisk Investigational Site
    Kashiwara-shi, Osaka, 582 0005, Japan
  • Novo Nordisk Investigational Site
    Kawagoe-shi, Saitama, 350 0851, Japan
  • Novo Nordisk Investigational Site
    Kitakyushu-shi, Fukuoka, 800 0252, Japan
  • Novo Nordisk Investigational Site
    Koriyama-shi, Fukushima, 963 8851, Japan
  • Novo Nordisk Investigational Site
    Kumamoto-shi,Kumamoto, 862 0976, Japan
  • Novo Nordisk Investigational Site
    Kurume-shi, Fukuoka, 839 0863, Japan
  • Novo Nordisk Investigational Site
    Miyazaki-shi, 880 0034, Japan
  • Novo Nordisk Investigational Site
    Naka-shi, Ibaraki, 311 0113, Japan
  • Novo Nordisk Investigational Site
    Niigata-shi, Niigata, 950 1104, Japan
  • Novo Nordisk Investigational Site
    Oita, 870 8511, Japan
  • Novo Nordisk Investigational Site
    Okawa-shi, Fukuoka, 831 0016, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 532 0003, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 545 8586, Japan
  • Novo Nordisk Investigational Site
    Ota-ku, Tokyo, 144 0035, Japan
  • Novo Nordisk Investigational Site
    Oyama-shi, Tochigi, 323 0022, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 060-0001, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 062 0007, Japan
  • Novo Nordisk Investigational Site
    Shimotsuke-shi, Tochigi, 329 0433, Japan
  • Novo Nordisk Investigational Site
    Shizuoka-shi, 424 0853, Japan
  • Novo Nordisk Investigational Site
    Tagajo-shi, 985 0852, Japan
  • Novo Nordisk Investigational Site
    Takatsuki-shi, Osaka, 569 1096, Japan
  • Novo Nordisk Investigational Site
    Tochigi, 329 0498, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 104 0044, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 113 0031, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 125 0054, Japan
  • Novo Nordisk Investigational Site
    Yamaguchi, 755 0067, Japan
  • Novo Nordisk Investigational Site
    Yokohama-shi, 235 0045, Japan
10

References and documents

Publications

  • Kaku K, Kiyosue A, Ono Y, Shiraiwa T, Kaneko S, Nishijima K, Bosch-Traberg H, Seino Y. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig. 2016 Jan;7(1):76-84. doi: 10.1111/jdi.12367. Epub 2015 Jul 14. Erratum In: J Diabetes Investig. 2016 Mar;7(2):279. doi: 10.1111/jdi.12470. PubMed 26816604 ↗
  • Kiyosue A, Seino Y, Nishijima K, Bosch-Traberg H, Kaku K. Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig. 2018 Jul;9(4):831-839. doi: 10.1111/jdi.12759. Epub 2017 Nov 24. PubMed 28984041 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Apr 2013, 15 months.

Results were first posted in May 2014, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2012
First posted
Jan 19, 2012
StartActual
Jan 10, 2012
Primary completionActual
Apr 26, 2013
CompletionActual
Apr 26, 2013
Results first posted
May 28, 2014
Last update
Dec 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01512108
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 19, 2012
Start date
Jan 10, 2012
Primary completion
Apr 26, 2013
Completion
Apr 26, 2013
Results posted
May 28, 2014
Last update
Dec 18, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion